Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.46 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.43 |
| ▸ | GGH | Q92820 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15202797 | 0.98 | BMP1 (0.49) | BMP1FOLH1NAALAD2RIMKLAANPEP | |
| SCHEMBL13377665 | 0.98 | BMP1 (0.49) | BMP1FOLH1NAALAD2RIMKLAANPEP | |
| SCHEMBL14553976 | 0.91 | BMP1 (0.51) | BMP1FOLH1NAALAD2RIMKLAANPEP | |
| SCHEMBL26568534 | 0.90 | BMP1 (0.42) | BMP1FOLH1NAALAD2RIMKLAANPEP | |
| SCHEMBL25513501 | 0.88 | FOLH1 (0.56) | BMP1FOLH1GNPATSIRT5 | |
| SCHEMBL14567065 | 0.88 | FOLH1 (0.56) | BMP1FOLH1GNPATSIRT5 | |
| SCHEMBL22316165 | 0.87 | FOLH1 (0.62) | BMP1FOLH1NAALAD2RIMKLAANPEP | |
| SCHEMBL8290794 | 0.86 | ANPEP (0.50) | BMP1FOLH1NAALAD2RIMKLAANPEP | |
| SCHEMBL16656710 | 0.86 | ANPEP (0.50) | BMP1FOLH1NAALAD2RIMKLAANPEP | |
| SCHEMBL6888354 | 0.86 | ANPEP (0.50) | BMP1FOLH1NAALAD2RIMKLAANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758426-B1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK AS (DK) | 2019-08-07 | — | — | EP | disclosed |
| US-8541368-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2013-09-24 | — | — | US | disclosed |
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GIPR, IAPP | BMP1 2102/4885FOLH1 303/4885NAALAD2 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.